Share

A drug naive parkinsonian patient successfully treated with weak electromagnetic fields.

R Sandyk

PAPERpubmedThe International journal of neuroscience1994Case reportEffect: benefitEvidence: Very low

Abstract

Brief cerebral application of picotesla (pT) electromagnetic fields (EMF) has been demonstrated an efficacious, revolutionary treatment modality for the therapy of Parkinson's disease (PD) with clinical benefits being evident in all motor aspects of the disease as well as in nonmotor symptoms such as mood, sleep, pain, sexual dysfunction, autonomic regulation and cognitive functions. Since treatment with pT EMF has involved PD patients who were treated with dopaminergic agents at the time they received EMF there may have been a synergistic interaction between dopaminergic drugs and EMF. The present communication concerns a 49-year-old male Parkinsonian patient with stage 3 disability on the Hoehn and Yahr scale (1967) who, in response to brief extracranial applications of pT EMF, demonstrated a marked improvement in motor, depressive symptomatology and cognitive functions and was classified as stage 1 several weeks later. This case is remarkable in that the patient did not receive treatment with dopaminergic drugs prior to or during the course of EMF therapy. It suggests that (a) pT range EMF may be efficacious as a monotherapy for PD and should be considered also as a treatment modality for de novo diagnosed patients, and (b) application of these EMF improves Parkinsonism by a mechanism which involves, among others, augmentation of dopaminergic and serotonergic neurotransmission.

AI evidence extraction

At a glance
Study type
Case report
Effect direction
benefit
Population
49-year-old male patient with Parkinson's disease (Hoehn and Yahr stage 3 at baseline)
Sample size
1
Exposure
therapeutic extracranial/cerebral application of picotesla electromagnetic fields · brief applications; several weeks follow-up
Evidence strength
Very low
Confidence: 74% · Peer-reviewed: yes

Main findings

A 49-year-old drug-naive Parkinson's disease patient reportedly showed marked improvement in motor symptoms, depressive symptomatology, and cognitive functions after brief extracranial applications of picotesla electromagnetic fields, with Hoehn and Yahr stage changing from 3 to 1 several weeks later.

Outcomes measured

  • Motor symptoms of Parkinson's disease
  • Depressive symptomatology/mood
  • Cognitive functions
  • Hoehn and Yahr stage

Limitations

  • Single-patient case report
  • No control/comparator described
  • Exposure parameters (e.g.
  • frequency
  • dose) not specified in abstract
  • Follow-up duration only described as 'several weeks'
  • Mechanistic claims are speculative and not directly demonstrated in the case description
View raw extracted JSON
{
  "study_type": "case_report",
  "exposure": {
    "band": null,
    "source": "therapeutic extracranial/cerebral application of picotesla electromagnetic fields",
    "frequency_mhz": null,
    "sar_wkg": null,
    "duration": "brief applications; several weeks follow-up"
  },
  "population": "49-year-old male patient with Parkinson's disease (Hoehn and Yahr stage 3 at baseline)",
  "sample_size": 1,
  "outcomes": [
    "Motor symptoms of Parkinson's disease",
    "Depressive symptomatology/mood",
    "Cognitive functions",
    "Hoehn and Yahr stage"
  ],
  "main_findings": "A 49-year-old drug-naive Parkinson's disease patient reportedly showed marked improvement in motor symptoms, depressive symptomatology, and cognitive functions after brief extracranial applications of picotesla electromagnetic fields, with Hoehn and Yahr stage changing from 3 to 1 several weeks later.",
  "effect_direction": "benefit",
  "limitations": [
    "Single-patient case report",
    "No control/comparator described",
    "Exposure parameters (e.g., frequency, dose) not specified in abstract",
    "Follow-up duration only described as 'several weeks'",
    "Mechanistic claims are speculative and not directly demonstrated in the case description"
  ],
  "evidence_strength": "very_low",
  "confidence": 0.74,
  "peer_reviewed_likely": "yes",
  "keywords": [
    "Parkinson's disease",
    "picotesla electromagnetic fields",
    "extracranial application",
    "drug-naive",
    "motor symptoms",
    "depression",
    "cognition",
    "Hoehn and Yahr"
  ],
  "suggested_hubs": [
    {
      "slug": "therapeutic-emf",
      "weight": 0.78,
      "reason": "Reports clinical use of weak (picotesla) EMF as a treatment modality for Parkinson's disease."
    }
  ]
}

AI can be wrong. Always verify against the paper.

AI-extracted fields are generated from the abstract/metadata and may be incomplete or incorrect. This content is for informational purposes only and is not medical advice.

Comments

Log in to comment.

No comments yet.

NNEMF synthesis

Synthesis pending.

Original record: rfsafe.org paper 5448

A drug naive parkinsonian patient successfully treated with weak electromagnetic fields. · Non-native EMF